Cellectis gets U.S. go-ahead to test 'off-the-shelf' cell therapy

(Reuters) - Cellectis has won U.S. regulatory approval to run an early clinical trial using its gene edited cell therapy product UCART123 for blood cancers, boosting the French biotech firm's ambitions in the hot area of cancer research.